Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00448149 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer
A Phase 1 study, sponsored by The Methodist Hospital Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT00448149 is a Phase 1 study that has completed, run by The Methodist Hospital Research Institute. The registered enrollment target is 55 participants.
The verdict
NCT00448149, a Phase 1 study, has completed, sponsored by The Methodist Hospital Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
The purpose of this study is to see whether the combination for RAD001 and Nexavar® works better when given together than they do alone. The purpose of the first phase of this study is to determine the best dose of RAD001 given with Nexavar®, and to see what effects, good and/or bad, the study drug has on the subject and the subject's tumor. This study will also observe side effects experienced by the subject.
Interventions
- DRUG Sorafenib
- DRUG RAD001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2006-12 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00448149
The ClinicalTrials.gov registry entry for NCT00448149 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Methodist Hospital Research Institute, which has 126 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sorafenib is the first listed.
NCT00448149 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00448149 about?
NCT00448149 is a clinical study titled "Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer". The purpose of this study is to see whether the combination for RAD001 and Nexavar® works better when given together than they do alone. The purpose of the first phase of this study is to determine the best dose of RAD001 given with Nexavar®, and to see what effects, good and/or bad, the study drug ...
What is the current status of trial NCT00448149?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2006-12. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00448149?
The interventions under investigation include: Sorafenib (DRUG), RAD001 (DRUG).
Who is sponsoring clinical trial NCT00448149?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.